MyotonicPipeline.com
Dyne Therapeutics
Approach: antibody-oligonucleotide conjugates
Status: Phase 1/2
Section of Dyne's website discussing myotonic dystrophy
Video on Dyne's website explaining its technology
Mar. 21, 2021 Patent Application
Article on Dyne's technology
Press Release on Dyne's launch
April 3, 2019 Endpoints article on Dyne launch
June 13, 2019 Press Release: Dyne Therapeutics Presents Nonhuman Primate Proof of Concept Data on FORCE™ Therapeutic Platform at International Myotonic Dystrophy Consortium Meeting (IDMC-12)
September 14, 2019 Presentation at Myotonic conference (starts at 40:30)
October 2019 abstract presented at World Muscle Society conference
Aug. 25, 2020 S1 filed in conjunction with IPO (data within filing)
Sept. 2020 Presentation at Myotonic Dystrophy Foundation annual conference (starts at 18:39)
Jan. 10, 2021 Press Release detailing preclinical data
Feb. 9, 2021 Myotonic Dystrophy Foundation presentation
May 2021 Investor DM1 Program Webcast
Oct. 2021 R&D day slides
May 14, 2021 Press Release regarding data presented at ASGCT conference
May 16, 2022 Press Release regarding data presented at ASGCT conference
July 12, 2022 Press Release announcing CTA clearance to start P1/2 trial in New Zealand